Just one day after Novartis laid out plans for its long-expected spinoff of its eye unit Alcon, the Swiss pharma giant found itself fending off a rumor that it also intends to wave goodbye to its generics business, Sandoz.
Novartis plans more ‘autonomy’ for Sandoz. But don’t confuse that with a spinoff: report
Leave a Comment